Learn Before
Findings supporting heparin use in COVID-19 patients for patients at high risk of coagulopathy from retrospective study in Wuhan, China
Overall, heparin use did not improve outcomes. However, in severe COVID-19 cases with a sepsis-induced coagulopathy (SIC) score of 4 or higher and patients with D-dimer levels above 6 times normal levels, heparin treatment reduced 28-day mortality rates.
- results for heparin vs. no anticoagulants by SIC score
- results for heparin vs. no anticoagulants by D-dimer level
- results for univariate analysis for other clotting factors
- patient characteristics
- SIC score
- methods
- discussion
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Findings supporting heparin use in COVID-19 patients for patients at high risk of coagulopathy from retrospective study in Wuhan, China
Heparin Studies Using RT4 Cells Pre-Treated with Anti-ACE2 Antibodies
Prophylactic and Therapeutic Serum Concentrations of Unfractionated Heparin (UFH)
Prophylactic and Therapeutic Serum Concentrations of Low Molecular Weight Heparins (LMWH)
SARS-CoV-2 S Protein May Have Multiple Heparin Binding Sites
Learn After
Differences in 28-day mortality of severe COVID-19 patients treated with unfractionated heparin or low molecular weight heparin (LMWH) compared to control group given no anticoagulant based on SIC score
Differences in 28-day mortality of severe COVID-19 patients by D-dimer level among those given unfractionated heparin or low molecular weight heparin (LMWH) compared to control group given no anticoagulant.
Evaluation of other predictors of 28-day mortality pertaining to clotting factors and heparin treatment
SIC score interpretation for COVID-19
Methods for evaluating heparin effectiveness in COVID-19 patients for patients at high risk of coagulopathy from retrospective study in Wuhan, China
Patient characteristics in study evaluating heparin effectiveness in COVID-19 patients for patients at high risk of coagulopathy from retrospective study in Wuhan, China
Discussion for evaluating 28-day mortality of severe COVID-19 patients treated with unfractionated heparin or low molecular weight heparin (LMWH) compared to control group